Cell and Gene Therapy Supply Chain Software Market Report and Forecast 2025-2034

The global cell and gene therapy supply chain software market was valued at USD 1.46 Billion in 2024, driven by the increasing prevalence of genetic disorders, cancer, and other chronic conditions across the globe. The market is anticipated to grow at a CAGR of 11.20% during the forecast period of 2025-2034, with the values likely to reach USD 4.22 Billion by 2034.

Cell and Gene Therapy Supply Chain Software Market Overview

Cell and gene therapy supply chain software is designed to optimise the logistics, storage, and distribution of biological products. It addresses the unique challenges of managing temperature-sensitive therapies, ensuring regulatory compliance, and tracking product integrity throughout the supply chain. This software enhances efficiency, transparency, and security, supporting the growth and scalability of the cell and gene therapy industry.

Cell and Gene Therapy Supply Chain Software Market Growth Drivers

Strategic Collaborations to Boost Market Growth

The increasing demand for efficient manufacturing solutions and advancements in data analytics are key drivers for market growth. In April 2024, Autolomous, a leader in manufacturing management systems, partnered with BioCentriq, a clinical-phase Cell Therapy CDMO. Their collaboration aims to revolutionise the process development and manufacturing of cell and gene therapies through Autolomous' innovative autoloMATE® platform. This fully cloud-native, no-code software is designed to improve data capture, operational logistics, and tech transfer. It will empower BioCentriq to optimise efficiency while ensuring top-tier quality and data integrity, significantly enhancing the capabilities of the cell and gene therapy sector. This partnership is poised to positively influence the market's growth in the forecast period, driving demand for advanced software solutions in process development and manufacturing.

Emphasis on Expertise and Precision to Foster Cell and Gene Therapy Supply Chain Software Market Demand

The rising complexity of clinical trials and regulatory requirements in the cell and gene therapy sector are driving the need for specialised supply chain software solutions. For instance, in January 2024, TrakCel, a recognised leader in cellular orchestration systems, launched its Consultancy Services aimed at providing valuable expertise to CGT developers. This service focuses on critical areas such as Chain of Identity Strategy, Data Protection Compliance, and Supply Chain Risk Assessment, addressing the unique challenges faced by therapy developers. By offering their extensive process development experience, TrakCel is poised to streamline operations, mitigate risks, and improve compliance, supporting the growth and evolution of the cell and gene therapy supply chain. This initiative will play a key role in accelerating the market’s expansion over the coming years, reinforcing the demand for expert-driven solutions in supply chain management.

Cell and Gene Therapy Supply Chain Software Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Increasing Demand for Real-Time Data and Analytics in Supply Chains

Real-time data and advanced analytics are becoming crucial in the cell and gene therapy supply chain software market. Companies are increasingly leveraging these tools to monitor inventory, manage cold-chain logistics, and track gene therapy products at every stage. This shift toward data-driven decision-making enables faster response times, minimizes delays, and ensures better product quality, driving market development.

Growing Focus on Cold-Chain Logistics and Temperature Monitoring to Boost Cell and Gene Therapy Supply Chain Software Market Value

As gene therapies often require strict temperature control, there is a growing trend towards incorporating cold-chain logistics solutions in supply chain software. Advanced monitoring systems and temperature-controlled packaging are crucial to maintaining product integrity. Supply chain software that offers real-time temperature tracking ensures compliance with regulatory standards, helping businesses mitigate risks associated with product degradation and enhancing market growth.

Integration of Artificial Intelligence and Automation Technologies to Impact the Cell and Gene Therapy Supply Chain Software Market Size Positively

Artificial intelligence (AI) and automation are becoming key drivers of efficiency in the cell and gene therapy supply chain. AI tools can predict demand fluctuations, optimise route planning, and improve inventory management, while automation streamlines processes like packaging and labelling. The integration of these technologies not only reduces human error but also accelerates timelines, positively impacting market value and operational scalability.

Rise of Blockchain for Enhanced Traceability and Security to Aid Cell and Gene Therapy Supply Chain Software Market Demand

Blockchain technology is gaining traction in the cell and gene therapy supply chain software market, offering a secure and transparent method for tracking products. By providing a tamper-proof record of each step in the supply chain, blockchain ensures the integrity and traceability of gene therapies. This innovation enhances regulatory compliance, reduces the risk of fraud, and supports market growth through improved security.

Cell and Gene Therapy Supply Chain Software Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Enterprise Manufacturing System (EMS)
• Laboratory Information Management System (LIMS)
• Inventory Management System (IMS)
• Quality Management System (QMS)
• Logistics Management System (LMS)
• Patient Management System (PMS)
• Others

Market Breakup by Application

• Manufacturing Component
• Sample Collection and Processing Component
• Logistics Component
• Patient Identification and Treatment Follow-up Component
• Others

Market Breakup by Deployment

• On-premises Deployment
• Cloud-based Deployment

Market Breakup by End User

• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Biobanks
• Research and Academic Institutes
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Cell and Gene Therapy Supply Chain Software Market Share

Market Segmentation Based on End Users to Witness Significant Growth

Pharmaceutical and biotechnology companies are likely to lead the market share based on end users, primarily due to the increasing development and commercialisation of advanced cell and gene therapies by pharmaceutical and biotechnology firms. These companies require robust software solutions to manage the complexities of gene therapy supply chains, including cold-chain logistics, regulatory compliance, and ensuring product integrity from production to delivery. The growing investment in gene therapies, particularly for rare and chronic diseases, is driving the demand for efficient, secure, and scalable supply chain solutions in this segment, giving it a dominant market share.

Cell and Gene Therapy Supply Chain Software Market Analysis by Region

North America leads the market due to its robust healthcare infrastructure, high adoption of advanced technologies, and a growing number of biopharma companies focused on gene and cell therapies. The presence of key industry players, strong regulatory support, and significant investments in research and development further propel market growth. Additionally, the rising demand for personalised medicine and innovative therapies in the region strengthens North America's dominant market share.

Leading Players in the Cell and Gene Therapy Supply Chain Software Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Azenta Life Sciences

Headquartered in Chelmsford, Massachusetts, Azenta Life Sciences was established in 2021. The company provides a comprehensive portfolio of integrated solutions for the cell and gene therapy supply chain, including cold-chain logistics, sample management, and automated storage systems. Azenta’s technologies are designed to ensure safe, efficient transportation and storage of biologics and gene therapy products globally.

Biocair

Founded in 1987 and headquartered in the UK, Biocair specialises in providing logistics and supply chain solutions for the life sciences industry. Its portfolio includes cold-chain transportation, temperature-controlled packaging, and specialised courier services tailored to cell and gene therapies. Biocair’s global presence ensures secure, compliant handling of complex biological products, supporting the growing demand for gene therapy supply chains.

BioLife Solutions

BioLife Solutions, based in Bothell, Washington, was established in 1987. The company offers advanced cell and gene therapy supply chain solutions, including cryopreservation media, controlled-rate freezers, and automated thawing systems. BioLife’s products support the safe storage, transport, and handling of biologics, particularly for cell and gene therapy applications, ensuring the preservation of critical therapies across the supply chain.

Cryoport Systems, LLC.

Cryoport Systems, LLC. is a leading provider of supply chain solutions for the life sciences industry, with a particular focus on temperature-controlled logistics for biological materials. Their services are crucial for industries such as cell and gene therapy, which require precise handling and transportation of sensitive materials like cells, tissues, and gene-modified products.

Other key players in the market include Lonza, NMDP BioTherapies, TraceLink Inc., LabVantage Solutions Inc., and TrakCel.

Key Questions Answered in the Cell and Gene Therapy Supply Chain Software Market

• What was the cell and gene therapy supply chain software market value in 2024?
• What is the cell and gene therapy supply chain software market forecast outlook for 2025-2034?
• What is the market breakup based on the type?
• What is the market breakup based on the application?
• What is the market breakup based on the deployment?
• What is the market breakup based on the end user?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major cell and gene therapy supply chain software market trends?
• Which type will lead the market segment?
• Which application will lead the market segment?
• Which deployment will lead the market segment?
• Which end user will lead the market segment?
• Who are the key players involved in the cell and gene therapy supply chain software market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?